spacer
home > pmps > winter 2019 > inhalation drug delivery: going generic, getting connected
PUBLICATIONS
Pharmaceutical Manufacturing and Packing Sourcer

Inhalation Drug Delivery: Going Generic, Getting Connected

Over the past five years, generic pharmaceuticals have grown more than twice as fast as patented prescription drugs, a trend that is likely to continue (1). Across the industry, organisations are facing growing pressure to speed up timelines and slim down operating budgets to stay ahead of the competition. Additionally, connected inhalation opportunities are beginning to impact the market, as addressing problems with adherence and usability becomes a priority. Pharma companies entering the market need a partner with a successful track record in inhalation, as well as end-to-end capabilities from formulation and development to contract manufacturing. There may never have been a time when trustworthy partners were more critical to the success of a pharma campaign.

Going Generic

While inhalation generics have been on the market for several years in Europe, there have not been any generic inhalers launched in the US. Filings have been made with the FDA over the years, yet, to date, none have been approved. While the reasons for the delays are not typically made public, the result is obvious: lack of patient access to generic medicines, increased costs, and delayed and/or reduced revenue in the long term to generic pharma providers.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer

spacer
3M
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Nemera announces a better drug deposition with RetroNose to enhance therapeutic efficacy of nasal treatments

After announcing a partnership with the Research Center for Respiratory Diseases (CEPR) of Inserm/University of Tours in April 2017, Nemera is happy to publish enhanced drug deposition results compared to classic nasal sprays with RetroNose.
More info >>

White Papers

Industrial Security in the Pharmaceutical Sector

COPA-DATA

As an attractive target for cyber attacks, pharmaceutical companies need to understand cyber security, assess weak points and implement the appropriate security measures. This white paper describes some of the most effective industrial security tools pharmaceutical companies have at their disposal in the era of Industry 4.0.
More info >>

 
Industry Events

World Pharma Week 2019

17-20 June 2019, Seaport World Trade Center, Boston

World Pharma Week will bring together a unique and international mix of large and medium pharmaceutical and biotech companies, CROs, leading universities and clinical research institutions, emerging companies and tool providers—making it a perfect meeting-place to share experience, foster collaborations across industry and academia, and evaluate emerging technologies.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement